NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Codexis, Inc. (CDXS) Stock Analysis

Codexis, Inc. (CDXS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CDXS

$1.46

+$0.04 (+2.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CDXS with… →

CDXS Key Statistics

As of Sep 4, 2026
Trading
Open
$1.43
Previous Close
$1.42
Day's Range
1.43–1.48
52-Week Range
0.96–2.98
Volume
757.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.53
Valuation
Market Cap
$159.88M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
13.53
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.06
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.33
Financials (FY)
Revenue (FY)
$70.39M+18.61%
Net Income (FY)
−$43.97M
Profit marginThe share of revenue left as profit after all costs and taxes.
−39.55%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
109.51M
1-Year Return
−39.67%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.15M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CDXS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−10.43%
2025−65.83%
2024+56.39%
2023−34.55%
2022−85.10%
2021+43.24%
2020+36.52%
2019−4.25%
2018+100.00%
2017+81.52%
2016 (partial year)+7.48%

As of September 4, 2026.

CDXS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$70.39M−$43.97M−62.5%
2024$59.35M−$65.28M−110.0%
2023$70.14M−$76.24M−108.7%
2022$138.59M−$33.59M−24.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$70.39M$61.05M−$38.33M−$43.97M−62.5%
2024$59.35M$43.06M−$58.35M−$65.28M−110.0%
2023$70.14M$57.33M−$54.80M−$76.24M−108.7%
2022$138.59M$100.56M−$31.71M−$33.59M−24.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CDXS Valuation vs Biotechnology Median

Median of 656 stocks
MetricCDXSBiotechnology medianvs median
P/S ratio2.0615.260.1x the median
Profit margin−39.55%0.00%39.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Codexis, Inc. (CDXS) carries a market capitalisation of $159.88M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 146.

The most recent close on file for CDXS is $1.46, dated September 4, 2026. That is +$0.04 (+2.82%) against the previous close. Over the past 52 weeks the price has ranged from $0.96 to $2.98. The latest close sits 52.08% above that 52-week low.

Financial Health

In fiscal 2025, Codexis, Inc. reported revenue of $70.39M. That is +18.61% against the prior fiscal year, when revenue was $59.35M. The same year closed with a net loss of $43.97M. The reported profit margin is −39.55%. That is 39.6 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.33.

Across the 4 fiscal years on file, revenue moves from $138.59M in 2022 to $70.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 13.53. Measured against sales, the shares trade at 2.06 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −39.67%. Across 10 years the annualized return works out at −10.22%. The reported beta is 2.53. Daily returns over the trailing 10 years annualize to a volatility of 71.95%.

Growth & Income

The record shows no dividend for CDXS.

Across the complete calendar years on file, 2018 returned +100.00% and 2022 returned −85.10%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −10.43% year to date.

Peer Comparison

Codexis, Inc. (CDXS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Codexis, Inc. CDXS $159.88M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Codexis, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Codexis, Inc.

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Visit website →